T
Tevogen Inc. (TVGN)
NGM – Real vaqt narxi. Valyuta: USD
6.47
-0.18 (-2.71%)
Yopilishda: Aug 12, 2026, 4:00 PM EDT
6.47
0.00 (0.00%)
Bozordan keyin: Aug 12, 2026, 4:10 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
6.47
-0.18 (-2.71%)
Yopilishda: Aug 12, 2026, 4:00 PM EDT
6.47
0.00 (0.00%)
Bozordan keyin: Aug 12, 2026, 4:10 PM EDT
Tevogen Inc., klinik bosqichdagi ixtisoslashgan immunoterapiya kompaniyasi, yuqumli kasalliklar, saraton va boshqa kasalliklarni davolash uchun tayyor, aniq T-hujayrali terapiyalarni ishlab chiqadi. Kompaniya TVGN 489ni ishlab chiqmoqda, bu ambulatory yuqori xavfli kattalar COVID-19 bemorlarini davolash uchun 1-faza klinik sinovini yakunladi; va B-hujayrali saraton immunokompromiteti bilan o'tkir SARS-CoV-2 bemorlarini davolash uchun 1-faza klinik sinovida, shuningdek, B-hujayrali saraton ko'rsatmasi bo'lgan boshqa B-hujayrali immunokompromiteti bilan o'tkir SARS-CoV-2 bemorlarini davolash uchun, shuningdek, Long COVIDni oldini olish va davolash uchun. U shuningdek, bachadon bo'yni saratonini davolash uchun preclinical sinov dori TVGN 920; orofarengeal saratonni davolash uchun preclinical sinov dori TVGN 960; ko'p sklerozni davolash uchun preclinical sinov dori TVGN 601; Epşteyn-Barr virusi bilan bog'liq limfomalarini davolash uchun preclinical sinov dori TVGN 930; va gepatit B ga qaratilgan mahsulot nomzodi TVGN 116ni ishlab chiqmoqda. U dori ishlab chiqish uchun sun'iy intellekt platformasini ham taklif etadi. Tevogen Inc. ilgari Tevogen Bio Holdings Inc. nomi bilan tanilgan va 2026-yil iyul oyida Tevogen Inc. nomini o'zgartirgan. Kompaniya 2020-yilda ro'yxatga olingan va Nyu-Jersi shtatining Uorren shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Neal Flomenberg M.D. | Chief Scientific Officer and Global R&D Lead |
| Dr. Ryan H. Saadi M.D., M.P.H. | Co-Founder, CEO & Chairperson |
| Mr. David E. Banko C.P.A. | Global Head of Government Affairs & Patient Access |
| Mr. Kirti Desai C.P.A. | Chief Financial Officer |
| Mr. Mittul Mehta | Chief Information Officer & Head of Tevogen.ai |
| Mr. Sadiq Khan M.B.A. | Chief Commercial Officer & Interim Head of Tevogen Generics |
| Mr. Stephen Chen M.B.A. | Chief Technical Officer |
| Mr. Tapan V. Shah | Head of Investor Relations & Corporate Development |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-03 | DEF 14A | formdef14a.htm |
| 2026-07-30 | 8-K | form8-k.htm |
| 2026-07-23 | PRE 14A | formpre14a.htm |
| 2026-07-10 | S-8 | forms-8.htm |
| 2026-06-12 | S-3 | forms-3.htm |
| 2026-05-15 | 10-Q | form10-q.htm |
| 2026-04-30 | 10-K/A | form10-ka.htm |
| 2026-04-22 | 8-K | form8-k.htm |
| 2026-03-31 | 10-K | form10-k.htm |
| 2026-03-25 | 8-K | form8-k.htm |